Clinical Trials

• Phase I clinical study of adoptive immunotherapy, characterized by the infusion of autologous Natural Killer (NK) cells, after enrichment and expansion, in patients with acute lymphoblastic leukemia (LLA) Philadelphia (Ph)+ in complete haematological remission but with persistent recurrent minimal residual disease (in collaboration with the Policlinico Umberto I, Sapienza University of Rome and GIMEMA).
• Phase I clinical study of IFN-DC-based cell therapy in association with Rituximab in patients with indolent non-Hodgkin's lymphoma (in collaboration with the Sant'Andrea Hospital, Sapienza University of Rome).

Phase I clinical study of immunotherapy with IFN-DC in association with chemotherapy in patients with advanced melanoma (in collaboration with the Istituto Dermopatico dell'Immacolata and the Sant'Andrea Hospital, Sapienza University of Rome). – Rozera et al, J Transl Medicine 2015

FaBioCell can provide support in the preparation of regulatory documents for the authorization process of new cell factories and authorization for clinical trials, such as Investigational Medicinal Product Dossier and Investigator Brochure.